Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

RZLT

Rezolute Inc

Feb 11 • 04:00PM ET

3.37

+0.30 9.77 %

Healthcare • Biotechnology • USA • NASD

Peers: ASND KRYS SWTX LGND RAPT SVRA IMTX UBX RKDA

| Held by: XBI IWM VTI VXF IWO SCHA VTWO IWC VHT BBC

Index	RUT	P/E	-	EPS (ttm)	-0.93	Insider Own	20.39%	Shs Outstand	91.04M	Perf Week	15.81%
Market Cap	312.49M	Forward P/E	-	EPS next Y	-0.69	Insider Trans	0.65%	Shs Float	73.82M	Perf Month	34.26%
Enterprise Value	161.75M	PEG	-	EPS next Q	-0.19	Inst Own	93.11%	Short Float	25.71%	Perf Quarter	-66.15%
Income	-77.18M	P/S	-	EPS this Y	28.54%	Inst Trans	-6.62%	Short Ratio	2.72	Perf Half Y	-45.65%
Sales	0.00M	P/B	2.08	EPS next Y	1.11%	ROA	-54.73%	Short Interest	18.98M	Perf YTD	42.80%
Book/sh	1.62	P/C	2.05	EPS next 5Y	19.83%	ROE	-59.23%	52W High	11.46 -70.58%	Perf Year	-29.50%
Cash/sh	1.64	P/FCF	-	EPS past 3/5Y	24.95% 22.65%	ROIC	-52.16%	52W Low	1.07 214.95%	Perf 3Y	21.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.43% 9.31%	Perf 5Y	-74.85%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	26.65%	Oper. Margin	-	ATR (14)	0.34	Perf 10Y	-93.87%
Dividend Ex-Date	-	Quick Ratio	15.15	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.69	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	15.15	EPS Q/Q	20.41%	SMA20	7.46%	Beta	0.51	Target Price	4.25
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-10.87%	Rel Volume	0.75	Prev Close	3.07
Employees	71	LT Debt/Eq	0.01	Earnings	Nov 06 AMC	SMA200	-43.20%	Avg Volume	6.98M	Price	3.37
IPO	May 08, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	25.68% -	Trades		Volume	5,225,985	Change	9.77%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-25	Downgrade	Wedbush	Outperform → Neutral	$1
Dec-11-25	Downgrade	Craig Hallum	Buy → Hold	$2
Dec-11-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Nov-05-24	Initiated	Wedbush	Outperform	$12
Aug-27-24	Initiated	Guggenheim	Buy	$11
Jul-17-24	Initiated	BTIG Research	Buy	$13
Jun-04-24	Initiated	Craig Hallum	Buy	$14
Apr-09-24	Initiated	Maxim Group	Buy	$8
Aug-02-22	Resumed	Canaccord Genuity	Buy	$17
Jun-15-22	Initiated	Cantor Fitzgerald	Overweight	$9
Sep-08-21	Initiated	ROTH Capital	Buy	$21
May-27-21	Initiated	Oppenheimer	Outperform	$25
May-25-21	Initiated	H.C. Wainwright	Buy	$21

Show Previous Ratings

Feb-04-26 07:00AM	Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -7.62%
Jan-14-26 11:58AM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire) +9.68%
Jan-07-26 07:00AM	Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism (GlobeNewswire) +23.04%
Dec-31-25 11:12AM	Rezolute's Phase 3 sunRIZE Study for Ersodetug Fails to Meet Primary and Secondary Endpoints Despite Analyst Backing (Insider Monkey) +7.76%
Dec-30-25 04:39PM	Insiders Made Their Bets in 2025-These Were the Top 5 Stocks They Bought (MarketBeat) -9.88%
09:30AM	Loading…
Dec-23-25 09:30AM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire) +18.05%
Dec-18-25 01:49PM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire) -7.96%
Dec-17-25 09:47AM	RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know (Zacks)
Dec-15-25 01:06PM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating RZLT Investors with Losses Encouraged to Contact the Firm (PR Newswire) -9.44%
09:35AM	Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a Turnaround (Zacks)
Dec-12-25 12:28PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily) +28.57%
11:52AM	Rezolute stock crashes after sole pipeline candidate fails Phase III (Clinical Trials Arena)
08:30AM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire)
05:18AM	Praxis tees up another approval filing; Geron turns to layoffs (BioPharma Dive)
Dec-11-25 07:59PM	Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure (Business Wire) -87.20%
06:41PM	Loading…
06:41PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily)
07:00AM	Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism (GlobeNewswire)
Dec-01-25 09:55AM	How Much Upside is Left in Rezolute (RZLT)? Wall Street Analysts Think 56.58% (Zacks) -5.66%
Nov-12-25 12:00PM	All You Need to Know About Rezolute (RZLT) Rating Upgrade to Buy (Zacks)
09:55AM	Can Rezolute (RZLT) Climb 49.4% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-10-25 05:30PM	Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.48%
Nov-06-25 04:05PM	Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update (GlobeNewswire) +12.08%
Nov-05-25 07:30AM	Rezolute to Host Virtual Investor Event on Ersodetug Development Program (GlobeNewswire) +5.06%
Oct-29-25 11:57AM	Is Rezolute Inc. (RZLT) One of the Top Long-Term Biotechnology Stocks to Buy (Insider Monkey)
Oct-15-25 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.89%
Oct-09-25 04:05PM	Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.34%
Sep-17-25 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire) +6.36%
07:05AM	Rezolute Stock: FDA Fast Track Fuels 2025 Breakout (MarketBeat)
Sep-02-25 07:30AM	Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism (GlobeNewswire)
Aug-27-25 07:30AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:30AM	Loading…
Aug-20-25 07:30AM	Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer (GlobeNewswire)
Aug-13-25 07:30AM	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Jul-22-25 07:30AM	Rezolute to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-09-25 07:30AM	Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) (GlobeNewswire) +6.24%
May-28-25 08:00AM	Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism (GlobeNewswire)
May-20-25 12:08PM	Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential (Insider Monkey)
May-13-25 04:05PM	Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-05-25 08:00AM	Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
May-01-25 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.32%
03:57AM	Rezolute: RZ402 Could Be A Surprise Candidate In The Making (Seeking Alpha)
Apr-25-25 04:30PM	Rezolute, Inc. Announces Closing of Underwritten Offering (GlobeNewswire)
Apr-23-25 08:05AM	Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants (GlobeNewswire) +27.65%
08:00AM	Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism ( HI ) (GlobeNewswire)
Apr-11-25 12:00PM	Rezolute (RZLT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-26-25 07:30AM	Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors (GlobeNewswire) -5.54%
Feb-12-25 04:05PM	Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-04-25 08:00AM	Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Jan-31-25 08:00AM	Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-07-25 08:00AM	Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Dec-05-24 08:00AM	Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-24 08:00AM	FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
Nov-07-24 04:05PM	Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-19-24 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.39%
Sep-09-24 07:30AM	FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study (GlobeNewswire) +22.07%
Aug-27-24 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-05-24 07:30AM	Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
Jul-31-24 08:00AM	Rezolute to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-27-24 08:00AM	Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire)
Jun-24-24 08:00AM	Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds (GlobeNewswire) +7.85%
Jun-14-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -23.45%
Jun-13-24 11:30PM	Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.84%
04:01PM	Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-30-24 08:00AM	Rezolute to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -6.33%
06:27AM	Rezolute's oral Eylea rival hits phase 2 goal, sending stock up and sparking partnership talk (FierceBiotech.com)
May-21-24 04:05PM	Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) (GlobeNewswire) +6.76%
May-15-24 10:54PM	RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024 (InvestorPlace)
04:05PM	Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-23-24 08:00AM	Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting (GlobeNewswire) -19.21%
Mar-20-24 02:33PM	Hedge Fund and Insider Trading News: Ken Griffin, Nelson Peltz, Palliser Capital, Elliott Management, Three Arrows Capital, Rezolute, Inc. (RZLT), Tesla Inc (TSLA), and More (Insider Monkey)
Mar-06-24 07:30AM	Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) (GlobeNewswire)
Feb-13-24 04:05PM	Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update (GlobeNewswire) +13.76%
Jan-24-24 08:00AM	Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer (GlobeNewswire) +6.37%
Jan-23-24 08:00AM	Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Dec-14-23 08:00AM	Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism (GlobeNewswire)
Dec-13-23 08:00AM	Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema ( DME ) (GlobeNewswire) +8.37%
Nov-24-23 11:14AM	Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an 'XBI-MAS' (Newsfile)
Nov-17-23 08:00AM	Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day (GlobeNewswire)
Nov-13-23 04:05PM	Rezolute Reports First Quarter Fiscal 2024 Results (GlobeNewswire) +12.22% -7.39%
Oct-17-23 08:00AM	Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism (GlobeNewswire) +6.52%
Oct-11-23 08:00AM	Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism (GlobeNewswire) -6.00%
Sep-14-23 04:05PM	Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Sep-06-23 07:00AM	Rezolute to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Jun-27-23 04:05PM	Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism (GlobeNewswire)
Jun-01-23 12:45PM	Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease (Newsfile) -7.51%
May-11-23 04:05PM	Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Mar-23-23 04:50PM	Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema (GlobeNewswire) -5.34%
Mar-08-23 07:00AM	Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert (GlobeNewswire) +7.44%
Feb-10-23 04:05PM	Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Dec-15-22 07:00AM	Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema (GlobeNewswire)
Nov-09-22 04:05PM	Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Nov-01-22 07:00AM	Rezolute to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-20-22 07:00AM	Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting (GlobeNewswire)
Sep-15-22 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress (GlobeNewswire)
Sep-07-22 07:00AM	Rezolute Announces Presentation at the 60th Annual ESPE Meeting (GlobeNewswire)
Aug-15-22 08:36AM	Here's What Rezolute, Inc.'s (NASDAQ:RZLT) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jun-01-22 07:00AM	Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer (GlobeNewswire)
May-12-22 04:05PM	Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress (GlobeNewswire) +6.15%
May-04-22 04:01PM	Rezolute to Host Corporate Update Call on May 4, 2022 (GlobeNewswire)

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The firm's antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hogenhuis Wladimir	Director	Dec 16 '25	Buy	1.69	5,650	9,548	119,675	Dec 17 04:14 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Dec 16 '25	Buy	1.70	28,000	47,600	308,352	Dec 17 04:13 PM
Evans Daron	CFO	Dec 15 '25	Buy	1.77	40,000	70,640	415,900	Dec 15 07:35 PM
Evans Daron	CFO	Dec 15 '25	Buy	1.79	5,000	8,938	7,000	Dec 15 07:35 PM
Elam Nevan C	CEO	Dec 15 '25	Buy	1.59	32,000	50,880	641,119	Dec 15 07:35 PM
Karnawat Sunil Ratilal	Chief Commercial Officer	Dec 15 '25	Buy	1.62	12,100	19,599	71,542	Dec 15 07:34 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Jun 25 '25	Buy	4.38	2,500	10,939	15,500	Jun 26 09:07 AM
Evans Daron	CFO	Jun 24 '25	Buy	4.05	5,000	20,250	268,900	Jun 24 12:41 PM
Kim Young-Jin	Director	Jun 13 '25	Buy	3.25	1,230,769	3,999,999	8,423,386	Jun 23 09:38 AM
KREHER NERISSA	Director	Jun 13 '25	Buy	3.25	3,076	9,997	37,576	Jun 23 09:12 AM
Hogenhuis Wladimir	Director	Mar 31 '25	Buy	2.92	6,758	19,733	84,025	Apr 01 03:52 PM
Elam Nevan C	CEO	Mar 27 '25	Buy	2.85	12,302	34,999	224,119	Mar 31 09:18 AM
Evans Daron	CFO	Mar 26 '25	Buy	2.89	10,000	28,900	237,900	Mar 28 08:40 AM
Evans Daron	CFO	Mar 26 '25	Buy	2.88	10,000	28,800	23,000	Mar 28 08:40 AM
Hogenhuis Wladimir	Director	Feb 18 '25	Buy	4.70	10,000	47,000	77,267	Feb 20 07:59 PM
Evans Daron	CFO	Dec 09 '25	Buy	5.04	10,549	53,167	131,900	Dec 10 09:11 AM

Open in Screener

TRDA

Entrada Therapeutics Inc

Feb 11 • 04:00PM ET

11.07

+0.25 2.31 %

Healthcare • Biotechnology • USA • NASD

TRDA Entrada Therapeutics Inc daily Stock Chart

Peers: MRNA REGN PFE GILD BNTX NVAX VRTX SRPT INCY RNA

| Held by: VTI IWM IWN VXF IBB VTWO SCHA IWC DFAS AVSC

Index	RUT	P/E	-	EPS (ttm)	-2.50	Insider Own	43.12%	Shs Outstand	38.22M	Perf Week	2.31%
Market Cap	423.09M	Forward P/E	-	EPS next Y	-4.11	Insider Trans	-1.21%	Shs Float	21.74M	Perf Month	11.26%
Enterprise Value	148.65M	PEG	-	EPS next Q	-1.15	Inst Own	48.65%	Short Float	4.12%	Perf Quarter	52.48%
Income	-103.45M	P/S	6.88	EPS this Y	-310.44%	Inst Trans	-3.10%	Short Ratio	3.78	Perf Half Y	114.53%
Sales	61.52M	P/B	1.24	EPS next Y	-16.29%	ROA	-21.39%	Short Interest	0.90M	Perf YTD	7.68%
Book/sh	8.91	P/C	1.29	EPS next 5Y	-	ROE	-27.11%	52W High	13.82 -19.90%	Perf Year	-9.56%
Cash/sh	8.55	P/FCF	-	EPS past 3/5Y	- -	ROIC	-26.61%	52W Low	4.93 124.54%	Perf 3Y	-31.58%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	93.11%	Volatility	7.72% 7.22%	Perf 5Y	-
Dividend TTM	-	EV/Sales	2.42	EPS Y/Y TTM	-248.91%	Oper. Margin	-194.50%	ATR (14)	0.75	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.08	Sales Y/Y TTM	-71.42%	Profit Margin	-168.16%	RSI (14)	52.57	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	14.08	EPS Q/Q	-208.16%	SMA20	0.01%	Beta	-0.11	Target Price	18.50
Payout	0.00%	Debt/Eq	0.15	Sales Q/Q	-91.75%	SMA50	3.16%	Rel Volume	0.63	Prev Close	10.82
Employees	183	LT Debt/Eq	0.14	Earnings	Nov 06 BMO	SMA200	41.18%	Avg Volume	236.87K	Price	11.07
IPO	Oct 29, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-12.77% -81.34%	Trades		Volume	148,733	Change	2.31%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-26	Initiated	Guggenheim	Buy	$20
Jan-28-26	Initiated	Oppenheimer	Outperform	$21
Dec-06-24	Initiated	ROTH MKM	Buy	$29
Jan-05-24	Initiated	Oppenheimer	Outperform	$22
Apr-03-23	Initiated	H.C. Wainwright	Buy	$25

Feb-05-26 06:00PM	Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates (Zacks) -6.93% +5.26%
Feb-04-26 07:40AM	Techne (TECH) Beats Q2 Earnings and Revenue Estimates (Zacks) -8.23%
07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-09-26 07:16AM	Entrada Therapeutics reports progress across development portfolio (TipRanks)
Jan-08-26 07:00AM	Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases (GlobeNewswire)
08:45AM	Loading…
Dec-30-25 08:45AM	The Biggest IPO of the Year Prompts Huge Insider Buy (24/7 Wall St.)
Dec-17-25 07:00AM	Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-04-25 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 08:30AM	Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-30-25 08:10AM	Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-29-25 07:46AM	Janux Therapeutics (JANX) Moves 8.8% Higher: Will This Strength Last? (Zacks) -6.26%
Oct-28-25 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-05-25 07:00AM	Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program (GlobeNewswire)
Sep-02-25 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:15AM	Loading…
Aug-06-25 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 10:15AM	Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks) -11.45%
Jun-03-25 07:00AM	Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors (GlobeNewswire)
Jun-02-25 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.11%
May-29-25 11:10AM	Entradas Phase I/II trial of DMD treatment authorised to begin in EU (Clinical Trials Arena)
May-28-25 07:00AM	Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping (GlobeNewswire)
May-08-25 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.64%
07:00AM	Entrada Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 10:01AM	Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
08:00AM	Arvinas, Entrada cut staff; Merck builds US hub for Keytruda (BioPharma Dive)
Apr-29-25 10:01AM	Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-10-25 09:30AM	Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? (Zacks) -5.08%
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-25-25 10:03AM	Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment (Clinical Trials Arena) -5.79%
07:00AM	Loading…
Mar-24-25 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping (GlobeNewswire)
Feb-27-25 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-26-25 06:11AM	AstraZenecas next breast cancer drug; Madrigals accelerating MASH launch (BioPharma Dive)
Feb-25-25 01:05PM	FDA removes clinical hold on Entradas Duchenne therapy (Clinical Trials Arena) -5.68%
Feb-24-25 07:00AM	Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 (GlobeNewswire)
Feb-12-25 07:58AM	Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Feb-04-25 07:19AM	Entrada gets UK MHRA authorisation to begin Phase I/II trial of DMD treatment (Clinical Trials Arena)
Feb-03-25 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy (GlobeNewswire)
Jan-30-25 04:05PM	Azenta Announces the Election of Dipal Doshi to its Board of Directors (PR Newswire)
Dec-18-24 07:00AM	Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.32%
Dec-07-24 05:25AM	Roth MKM starts overlooked Entrada Therapeutics with Buy rating (TipRanks)
Nov-25-24 08:50AM	Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Nov-05-24 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-09-24 07:00AM	Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-24-24 07:00AM	Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development (GlobeNewswire) +5.70%
Sep-17-24 08:30AM	ashibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors (Business Wire)
Sep-06-24 07:00AM	Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program (GlobeNewswire)
Aug-13-24 08:20AM	Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates (Zacks) +11.26%
07:00AM	Entrada Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-25-24 09:55AM	Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High? (Zacks) +5.75%
Jul-12-24 09:33AM	Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last? (Zacks)
Jun-24-24 07:15AM	Entrada Therapeutics Announces $100 Million Registered Direct Offering (GlobeNewswire)
06:00AM	Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-03-24 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-21-24 09:55AM	Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet (Zacks)
May-20-24 05:32PM	Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing (MT Newswires)
May-16-24 07:02PM	Director Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
04:35PM	Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing (MT Newswires)
07:00AM	Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-07-24 01:53PM	TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Entrada Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-10-24 03:29PM	Insiders are Piling into These 5 Healthcare Stocks in 2024 (Insider Monkey) -5.72%
Apr-04-24 02:00PM	The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc. (PR Newswire)
Mar-27-24 01:27AM	Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
Mar-15-24 05:31AM	Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials (GuruFocus.com)
Mar-13-24 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +9.76%
Feb-07-24 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-29-24 08:14AM	Time to Pull the Trigger, Says Oppenheimer About These 3 Stocks (TipRanks)
Jan-03-24 07:00AM	Entrada Therapeutics Promotes Nathan J. Dowden to President (GlobeNewswire) -9.03%
Dec-28-23 07:01AM	Entrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 Shares (GuruFocus.com)
Nov-23-23 11:47AM	Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug (Zacks)
Nov-22-23 07:00AM	Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy (GlobeNewswire) -31.85%
Nov-07-23 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue Estimates (Zacks) +8.63%
08:06AM	Entrada Therapeutics Inc (TRDA) Reports Q3 2023 Earnings, Net Income of $35.5 Million (GuruFocus.com)
07:00AM	Entrada Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-12-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -9.47%
Sep-21-23 07:00AM	Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Sep-16-23 01:01AM	Insider Sell: Entrada Therapeutics Inc CEO Dipal Doshi Sells 1,000 Shares (GuruFocus.com)
Sep-07-23 07:00AM	Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community (GlobeNewswire) +5.48%
Aug-29-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Entrada Therapeutics Appoints Gina Chapman to its Board of Directors (GlobeNewswire)
Aug-08-23 08:40AM	Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +10.47%
07:00AM	Entrada Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 06:36AM	Entrada Therapeutics (NASDAQ:TRDA) pulls back 16% this week, but still delivers shareholders notable 33% return over 1 year (Simply Wall St.)
Aug-01-23 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Jul-21-23 06:43AM	New Strong Buy Stocks for July 21st (Zacks)
Jun-06-23 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire) +6.54%
May-15-23 06:03AM	Some Analysts Just Cut Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Estimates (Simply Wall St.)
May-13-23 08:03AM	Entrada Therapeutics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now (Simply Wall St.)
May-10-23 07:00AM	Entrada Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-30-23 10:26AM	We Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Apr-04-23 07:00AM	Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors (GlobeNewswire) -5.07%
Mar-29-23 07:00AM	Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference (GlobeNewswire)
Mar-08-23 06:02AM	Entrada Therapeutics, Inc. (NASDAQ:TRDA) Is About To Turn The Corner (Simply Wall St.) +5.94%
Mar-06-23 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 07:00AM	Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-09-23 07:00AM	Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
Jan-09-23 07:00AM	Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable (GlobeNewswire) +6.95%

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV) therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The company's oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. Entrada Therapeutics was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 21 '25	Sale	9.98	8,910	88,932	110,026	Nov 24 04:30 PM
BAKER BROS. ADVISORS LP	10% Owner	Nov 20 '25	Buy	9.07	28,867	261,846	4,691,392	Nov 24 04:09 PM
KORY WENTWORTH	Officer	Nov 21 '25	Proposed Sale	9.17	8,910	81,705		Nov 21 04:45 PM
PARMAR KUSH	Director	Nov 14 '25	Sale	8.80	200,000	1,760,000	2,963,066	Nov 18 04:36 PM
5AM Ventures V, L.P.	10% Owner	Nov 14 '25	Sale	8.80	200,000	1,760,000	2,963,066	Nov 18 04:34 PM
5AM Ventures V, L.P.	Affiliated Stockholder	Nov 14 '25	Proposed Sale	8.80	200,000	1,760,664		Nov 14 04:30 PM
BAKER BROS. ADVISORS LP	10% Owner	Nov 12 '25	Buy	7.76	100,736	781,638	4,664,924	Nov 12 05:34 PM
BAKER BROS. ADVISORS LP	10% Owner	Nov 11 '25	Buy	7.50	46,434	348,193	4,572,549	Nov 12 05:34 PM
BAKER BROS. ADVISORS LP	10% Owner	Nov 10 '25	Buy	7.21	30,874	222,756	4,529,969	Nov 12 05:34 PM
PARMAR KUSH	Director	Jul 09 '25	Sale	7.50	27,000	202,554	1,093,313	Jul 11 05:27 PM
5AM Ventures V, L.P.	10% Owner	Jul 09 '25	Sale	7.50	20,065	150,528	3,163,066	Jul 11 05:25 PM
5AM Ventures V, L.P.	10% Owner	Jul 09 '25	Sale	7.50	6,935	52,026	1,093,313	Jul 11 05:25 PM
5AM Opportunities I, L.P.	Director	Jul 09 '25	Proposed Sale	7.50	6,935	52,025		Jul 09 05:04 PM
5AM Ventures V, L.P.	Director	Jul 09 '25	Proposed Sale	7.50	20,065	150,528		Jul 09 05:02 PM
PARMAR KUSH	Director	Jun 27 '25	Sale	6.91	75,000	518,250	1,113,092	Jul 01 08:33 PM
PARMAR KUSH	Director	Jul 01 '25	Sale	7.12	25,000	178,065	1,100,248	Jul 01 08:33 PM
PARMAR KUSH	Director	Jun 30 '25	Sale	6.81	25,000	170,318	1,106,670	Jul 01 08:33 PM
5AM Ventures V, L.P.	10% Owner	Jun 27 '25	Sale	6.91	55,735	385,129	3,220,287	Jul 01 08:32 PM
5AM Ventures V, L.P.	10% Owner	Jun 27 '25	Sale	6.91	19,265	133,121	1,113,092	Jul 01 08:32 PM
5AM Ventures V, L.P.	10% Owner	Jul 01 '25	Sale	7.12	18,578	132,324	3,183,131	Jul 01 08:32 PM
5AM Ventures V, L.P.	10% Owner	Jun 30 '25	Sale	6.81	18,578	126,566	3,201,709	Jul 01 08:32 PM
5AM Ventures V, L.P.	10% Owner	Jul 01 '25	Sale	7.12	6,422	45,741	1,100,248	Jul 01 08:32 PM
5AM Ventures V, L.P.	10% Owner	Jun 30 '25	Sale	6.81	6,422	43,751	1,106,670	Jul 01 08:32 PM
5AM Ventures V, L.P.	Director	Jul 01 '25	Proposed Sale	7.12	18,578	132,324		Jul 01 05:03 PM
5AM Opportunities I, L.P.	Director	Jul 01 '25	Proposed Sale	7.12	6,422	45,737		Jul 01 05:01 PM
5AM Opportunities I, L.P.	Director	Jun 30 '25	Proposed Sale	6.81	6,422	43,751		Jun 30 05:09 PM
5AM Ventures V, L.P.	Director	Jun 30 '25	Proposed Sale	6.81	18,578	126,566		Jun 30 05:06 PM
5AM Opportunities I, L.P.	Director	Jun 27 '25	Proposed Sale	6.91	19,265	133,121		Jun 27 05:05 PM
5AM Ventures V, L.P.	Director	Jun 27 '25	Proposed Sale	6.91	55,735	385,129		Jun 27 05:03 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Apr 03 '25	Option Exercise	2.10	11,134	23,381	120,670	Apr 04 04:34 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 17 '25	Sale	10.67	1,784	19,035	109,536	Mar 19 04:32 PM
KORY WENTWORTH	Officer	Mar 17 '25	Proposed Sale	10.81	1,784	19,285		Mar 17 04:32 PM

RZLT

Rezolute Inc

TRDA

Entrada Therapeutics Inc

Upgrade your FINVIZ experience